Patents Assigned to Centocor, Inc.
  • Method for treating psoriasis by administering an anti-il-12 antibody
    Patent number: 7279157
    Abstract: The present invention relates to an anti-IL-12 antibody, including isolated nucleic acids that encode an anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: October 9, 2007
    Assignee: Centocor, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Recombinant A2-specific TNF?-specific antibodies
    Patent number: 7276239
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: October 2, 2007
    Assignees: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Recombinant A2-specific TNF?-specific antibodies
    Patent number: 7252823
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: August 7, 2007
    Assignees: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • IL-23p40 specific immunoglobulin derived proteins
    Patent number: 7252971
    Abstract: An anti-IL-23 specific human Ig derived protein is useful in therapeutic and diagnostic compositions, methods and devices. The anti-IL-23 Ig derived protein preferably includes one or more of the Seg 1, Seg 2, and Seg 3 epitopes of the p40 subunit of IL-23.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: August 7, 2007
    Assignee: Centocor, Inc.
    Inventors: Jacqueline Benson, Mark Cunningham, Jeffrey Luo
  • Anti-TNF antibodies, compositions, methods and uses
    Patent number: 7250165
    Abstract: The present invention relates to at least one novel anti-TNF antibodies, including isolated nucleic acids that encode at least one anti-TNF antibody, TNF, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: July 31, 2007
    Assignee: Centocor, Inc.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • IL-23p40 specific antibody
    Patent number: 7247711
    Abstract: Novel anti-IL-23p40 specific human Ig derived proteins, including, without limitation, antibodies, fusion proteins, and mimetibodies, isolated nucleic acids that encode the anti-IL-23p40 Ig derived proteins, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, are useful for therapeutic compositions, methods and devices. Preferably, the anti-IL-23p40 specific human Ig derived proteins do not bind the p40 subunit of IL-12 and, thus, do not neutralize IL-12-related activity.
    Type: Grant
    Filed: May 6, 2004
    Date of Patent: July 24, 2007
    Assignee: Centocor, Inc.
    Inventors: Jacqueline Benson, Mark Cunningham
  • Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
    Patent number: 7241733
    Abstract: The present invention relates to at least one novel human EPO mimetic CH1 deleted mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic CH1 deleted mimetibody or specified portion or variant, CH1 deleted mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: July 10, 2007
    Assignee: Centocor, Inc.
    Inventors: George A. Heavner, David M. Knight, John Ghrayeb, Bernard J. Scallon, Thomas C. Nesspor, Karen A. Kutoloski
  • Anti-TNF antibody fragments
    Patent number: 7227003
    Abstract: Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: June 5, 2007
    Assignees: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight, Scott A. Siegel
  • Methods of treating cachexia with chimeric anti-TNF antibodies
    Patent number: 7226593
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-?(TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: January 10, 2002
    Date of Patent: June 5, 2007
    Assignees: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods of treatment of fistulas in Crohn's disease with anti-TNF antibodies
    Patent number: 7223396
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: May 29, 2007
    Assignees: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods of inhibiting TNF? in patients with neoplastic disease
    Patent number: 7214376
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: May 8, 2007
    Assignees: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods of treating disseminated intravascular coagulation by multiple administration of anti-TNF antibodies
    Patent number: 7204985
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: April 17, 2007
    Assignees: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods of treating psoriasis with anti-TNF antibodies
    Patent number: 7192584
    Abstract: The invention relates to anti-TNF antibodies, fragments, regions and derivatives thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in methods of treating psoriasis, as well as polynucleotides coding for murine and chimeric anti-TNF antibodies, and methods of producing anti-TNF antibodies, fragments, regions and derivatives thereof.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: March 20, 2007
    Assignees: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods of treating rheumatoid arthritis by multiple administration of anti-TNF antibodies
    Patent number: 7179466
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: February 20, 2007
    Assignees: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghraveb, David Knight, Scott Siegel
  • Recombinant anti-TNF-? antibodies
    Patent number: 7179893
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: April 7, 2006
    Date of Patent: February 20, 2007
    Assignees: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods of inhibiting TNF? in patients with cancer
    Patent number: 7169388
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: January 30, 2007
    Assignees: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods of treating inflammation associated with viral infection with anti-TNF antibodies
    Patent number: 7169386
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: January 10, 2002
    Date of Patent: January 30, 2007
    Assignees: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods of treating joint inflammation with anti-TNF antibodies
    Patent number: 7166284
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: January 23, 2007
    Assignees: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Anti-IL-12 antibodies and compositions
    Patent number: 7166285
    Abstract: The present invention relates to an anti-IL-12 antibody, including isolated nucleic acids that encode an anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: January 23, 2007
    Assignee: Centocor, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Anti-integrin antibodies, compositions, methods and uses
    Patent number: 7163681
    Abstract: The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: January 16, 2007
    Assignee: Centocor, Inc.
    Inventors: Jill Giles-Komar, Linda Snyder, Mohit Trikha, Marian T. Nakada